Direct AT2R stimulation with compound 21 significantly decreased renal TNF-α, IL-6, and TGF-β1 and increased NO and cGMP levels in the clipped kidneys of 2K1C hypertensive rats.
Does direct AT2R stimulation with compound 21 reduce early renal inflammatory responses in a rat model of renovascular hypertension?
Direct AT2R stimulation with compound 21 reduces early renal inflammation and improves NO and cGMP production in a rat model of renovascular hypertension, independent of blood pressure changes.
Angiotensin II type 2 receptor (AT₂R) counteracts most effects of angiotensin II type 1 receptor (AT(1)R). We hypothesized that direct AT₂R stimulation reduces renal production of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and transforming growth factor-β1 (TGF-β1) and enhances the production of nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP) in the clipped kidney of 2-kidney, 1-clip (2K1C) hypertension rat model. We used Sprague-Dawley rats to evaluate changes in renal interstitial fluid recovery levels of TNF-α, IL-6, NO, and cGMP; renal expression of AT₁R, AT₂R, TGF-β1, TNF-α, and IL-6 in sham and 2K1C rats treated for 4 days with vehicle, AT₂R agonist compound 21 (C21), or AT₂R antagonist PD123319 (PD), alone and combined (n=6, each group). Systolic blood pressure increased significantly in 2K1C and was not influenced by any treatment. Clipped kidneys showed significant increases in renal expression of AT₁R, AT₂R, TNF-α, IL-6, TGF-β1 and decreases in NO and cGMP levels. These factors were not influenced by PD treatment. In contrast, C21 caused significant decrease in renal TNF-α, IL-6, TGF-β1 and an increase in NO and cGMP levels. Combined C21 and PD treatment partially reversed the observed C21 effects. Compared to sham, there were no significant changes in TNF-α, IL-6, TGF-β1, NO, or cGMP in the nonclipped kidneys of 2K1C animals. We conclude that direct AT₂R stimulation reduces early renal inflammatory responses and improves production of NO and cGMP in renovascular hypertension independent of blood pressure reduction.
Matavelli et al. (Wed,) conducted a other in Renovascular hypertension. AT2R agonist compound 21 (C21) vs. Vehicle or AT2R antagonist PD123319 (PD) was evaluated on Renal interstitial fluid recovery levels of TNF-α, IL-6, NO, and cGMP, and renal expression of AT1R, AT2R, TGF-β1, TNF-α, and IL-6. Direct AT2R stimulation with compound 21 significantly decreased renal TNF-α, IL-6, and TGF-β1 and increased NO and cGMP levels in the clipped kidneys of 2K1C hypertensive rats.